• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Drug-Device Combinations

SiBionics reports strong CGM, ketone monitoring data

September 24, 2025 By Sean Whooley

SiBionics GS3 CGM (1)

SiBionics announced the presentation of new data supporting its continuous glucose monitoring (CGM) and ketone monitoring (CKM) devices. The China-based company shared findings for its integrated CGM and CKM diabetes management solution as well. It showcased the technology at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria. […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: EASD 2025, SiBionics

Medtronic begins rollout of MiniMed 780G with Instinct sensor made by Abbott

September 23, 2025 By Sean Whooley

Medtronic MiniMed 780G Abbott Instinct Sensor (1)

Medtronic (NYSE:MDT) announced that its Instinct sensor, made by Abbott, is now available to order with the MiniMed 780G pump. The medtech giant’s diabetes unit — one of the largest diabetes tech businesses in the world — earlier this month picked up FDA clearance for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC). […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Medtronic, minimed

B. Braun puts $20M in IV manufacturing expansion in Pennsylvania

September 19, 2025 By Sean Whooley

bbraun logo

B. Braun announced that it plans to invest $20 million to expand and modernize a medical device manufacturing facility in Pennsylvania. The project should create at least 200 new, full-time jobs over the next three years and retain 1,704 existing positions at the Lehigh Valley plant. The Commonwealth of Pennsylvania put forth its support for […]

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: B. Braun

Analysts label Embecta ‘undervalued’ and poised for growth

September 19, 2025 By Sean Whooley

BD Diabetes Spinoff Embecta

BTIG analysts maintain a “Buy” rating for Embecta (Nasdaq:EMBC) after meetings with company officials highlighted plans for growth. Marie Thibault, Sam Eiber and Alexandra Pang hosted Embecta CEO Devdatt Kurdikar and Head of Investor Relations Pravesh Khandelwal this week. Following the in-person and virtual meetings, the analysts maintain confidence in the former BD Diabetes unit’s […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology, Wall Street Beat Tagged With: embecta

Vivani sets date for neuromod spin-off as focus turns to drug delivery implant

September 17, 2025 By Sean Whooley

Vivani Medical Cortigent

Vivani Medical (Nasdaq:VANI) announced today that it set a record date for the approved spin-off of its Cortigent subsidiary. In May, the Alameda, California-based company announced plans to spin off Cortigent, its division developing brain implants. The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, Neurological, Technology, Wall Street Beat Tagged With: Cortigent, Vivani Medical

Tandem reports positive outcomes for automated insulin delivery in type 2 regardless of C-peptide levels

September 16, 2025 By Sean Whooley

Tandem Diabetes Care t_slim X2 with control IQ +

Tandem Diabetes Care (Nasdaq:TNDM) today announced study findings highlighting the benefits of its automated insulin delivery system. Findings from the “Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level” study were published in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP trial, found that Control-IQ+ automated […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Tandem Diabetes Care

Dexcom CEO takes temporary leave of absence

September 16, 2025 By Sean Whooley

Dexcom CEO Kevin Sayer

Dexcom (Nasdaq:DXCM) today filed an SEC form to announce that Chair and CEO Kevin Sayer is taking a temporary medical leave of absence. Sayer’s leave went into effect on Sept. 14, 2025. The Dexcom board appointed Jake Leach to serve as interim principal executive officer, in addition to his current duties as president and COO. Leach […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom, Personnel Moves

Modular Medical can start insulin patch pump feasibility study

September 16, 2025 By Sean Whooley

Modular Medical Pivot insulin patch pump

Modular Medical (Nasdaq:MODD) announced that it received Institutional Review Board (IRB) approval to study its next-generation insulin pump. San Diego-based Modular Medical can now conduct an in-house feasibility study for its next-generation Pivot insulin delivery system. The company plans for the study of the new pump to use sterile saline. Modular Medical unveiled Pivot, its […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Technology Tagged With: modularmedical

Roche wins CE mark for CGM, mySugr integration, presents positive clinical data

September 16, 2025 By Sean Whooley

Roche Accu-Chek SmartGuide IBM Predict

Roche announced today that it received CE mark for the integration of its Accu-Chek SmartGuide CGM with the mySugr app. The Basel, Switzerland-based company — one of the largest diabetes tech companies in the world — announced the milestone, along with new real-world evidence for its continuous glucose monitoring (CGM) solution, at the European Association […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: EASD 2025, Roche, Roche Diabetes Care

Medtronic reports positive 3-year automated insulin delivery data

September 16, 2025 By Sean Whooley

George Kelesidis Medtronic MiniMed 780G (1) (1)

Medtronic (NYSE:MDT) today shared three-year real-world evidence highlighting improvements with its MiniMed 780G automated insulin delivery system. MiniMed 780G, the company’s latest-generation AID system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs. Data demonstrated rapid, sustained […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: EASD 2025, Medtronic, minimed

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Interim pages omitted …
  • Page 374
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS